Seroprevalence against Sars-CoV-2 after booster vaccination in a prison in Alicante (Spain)

Bibliographic Data

ID22069494
AuthorsAna C Montagud (0000-0002-0647-0551, Hospital Quirón Torrevieja, corresponding author), Raúl Moragues (0000-0003-0380-7910, University of Alicante, corresponding author), Nancy Vicente-Alcalde (0000-0002-8168-4496, Universidad Cardenal Herrera CEU), Emilia Montagud (Hospital Quirón Torrevieja), José Antonio Hurtado-Sánchez (University of Alicante), José Tuells (0000-0003-1159-429X, University of Alicante)
Year2025
Volume13
Pages1490809-1490809
Publication date2025-01-28
Open AccessYes
TypeARTICLE
VenueFrontiers in Public Health (JOURNAL)
Journal identifiersISSN: 2296-2565 • E-ISSN: 2296-2565
PublisherFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2025.1490809
PMID39935883
OpenAlexW4406882431
LanguageEN
References cited37

Background: Confinement conditions in prison communities are associated with increased susceptibility to infectious outbreaks. The COVID-19 pandemic has been characterized by high transmissibility and clinical severity resulting in a high number of infections and deaths worldwide. Vaccination has been a crucial tool in mitigating its devastating effects. The aim of this study is to asses the prevalence of antibodies against the Spike protein of SARS-CoV-2 in vaccinated prisoners and staff at a specific prison in Alicante. Methods: A cross-sectional epidemiological study was designed for the population in scope using a rapid lateral flow immunochromatography serological test, conducted on July 27, 2023. Demographic and clinical variables were collected through a questionnaire. Statistical analysis was performed using the SPSS 29.0 software. Results: A total of 560 people participated in the study; the predominant profile was men (77.3%) with an average age of 45.7 years. 71.4% of subjects were prisoners and 28.6% were prison staff. Regarding the detection of anti-SARS-CoV-2 antibodies obtained through serological test, 60.9% of the sample gave a positive result. 69.1% of participants received the last dose in 2022 or later and 62.2% received booster doses. The vaccines administered in the last dose were Biontech/Pfizer and Moderna in 88.6% of the cases. 59.5% of sample had suffered from COVID-19 and 67.0% did not have any clinical comorbidity. In the regression analysis, it was observed that the variables with a stronger statistical relationship with presence of anti-SARS-CoV-2 antibodies were: the number of years since last vaccine dose was received (aOR: 0.08; 95%CI: 0.05; 0.16) the number of vaccine doses received (aOR: 4.8; 95%CI: 2.9; 8.0) and presenting any comorbidity (aOR: 4.3; 95%CI: 2.4; 8.0). The staff received more booster doses and obtained a better response to seropositivity, with 72.5% of anti-SARS-CoV-2 result positive while prisoners reached 56.3%. Conclusion: The COVID-19 vaccination status within the prison community following the initiation of primary immunization and subsequent booster doses, shows a low immunization coverage (60.9%), which is below expectations given the immunization strategies implemented since the start of the pandemic. There are notable differences in vaccination rates between prison staff and prisoners. These disparities are concerning, and authorities responsible for prison public health should take a more proactive approach to ensuring vaccination among prisoners

Antibody · Disease · Environmental health · Geography · Outbreak · Pandemic · Population · Prison · Serology · Seroprevalence · Vaccination · COVID-19 Clinical Research Studies · Demography · Medicine · SARS-CoV-2 and COVID-19 Research · vaccines and immunoinformatics approaches · Epidemiology · Immunology · Internal Medicine · Virology

Tools

Open DOIOpen Access